RNS Number : 2439Q

Venture Life Group PLC

25 February 2021

25 February 2021


("Venture Life" "VLG" or the "Company")

Investor Presentation

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market is pleased to announce that Jerry Randall (CEO), Sharon Daly (Chief Commercial Officer) and Andrew Waters (CFO) will provide a live presentation relating to their full year results for the year ended 31(st) December 2020 via the Investor Meet Company platform on 29th Mar 2021 at 1:00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VENTURE LIFE GROUP PLC via:


Investors who already follow Venture Life Group on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

 Venture Life Group PLC                                +44 (0) 1344 578004 
 Jerry Randall, Chief Executive Officer 
                                                        +44 (0) 20 7397 
  Cenkos Securities plc (Nomad and Joint Broker)         8900 
 Michael Johnson / Russell Kerr (Sales) 
  Stephen Keys / Camilla Hume (Corporate Finance) 
                                                        +44 (0) 20 7496 
  N+1 Singer (Joint Broker)                              3000 
 Jonathan Dighe (Sales) 
  Shaun Dobson / Carlo Spingardi (Corporate Finance) 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 25, 2021 02:00 ET (07:00 GMT)

Grafico Azioni Venture Life (LSE:VLG)
Da Ago 2021 a Set 2021 Clicca qui per i Grafici di Venture Life
Grafico Azioni Venture Life (LSE:VLG)
Da Set 2020 a Set 2021 Clicca qui per i Grafici di Venture Life